Corrigendum to “Smoking and Risk of Colorectal Cancer Sub-classified by Tumor-infiltrating T Cells” by Tsuyoshi Hamada et al. JNCI J Natl Cancer Inst (2019) 111(1): Volume 111, Issue 1, 1 January 2019, Pages 42–51, https://doi.org/10.1093/jnci/djy137
The following information has been added to the Notes section of the manuscript: CSF has been a consultant and/or a scientific advisor for Eli Lilly, Entrinsic Health, Pfizer, Merck, Sanofi, Roche, Genentech, Merrimack Pharmaceuticals, Unum Therapeutics, Dicerna, Bayer, Celgene, Agios, Gilead Sciences, Bain Capital, Five Prime Therapeutics, Taiho, and KEW and serves on the Board of Directors for CytomX Therapeutics; in that capacity, he receives a stipend and was awarded unexercised stock options, but owns no stock. While the authors did not consider the aforementioned outside activities to be a conflict of interest or directly relevant to the submitted work, the authors wish to add this disclosure in the spirit of full transparency.